Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $68.00 → $92.00 | Neutral → Overweight | Piper Sandler |
| 1/3/2024 | $83.00 | Outperform | Robert W. Baird |
| 12/11/2023 | $75.00 | Outperform | TD Cowen |
| 4/20/2023 | $80.00 | Overweight | Morgan Stanley |
| 8/22/2022 | $64.00 → $49.00 | Buy → Neutral | Goldman |
| 7/7/2022 | $74.00 | Buy | Mizuho |
| 6/14/2022 | $75.00 | Buy | UBS |
| 4/22/2022 | $59.00 | Neutral | Piper Sandler |
8-K - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
10-Q - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
8-K - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Results show robust efficacy and favorable safety and tolerability profile for CAPLYTA BEDMINSTER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced presentations about lumateperone including the results from Phase 3 adjunctive Major Depressive Disorder (MDD) Studies 501 and 502 at Psych Congress held O
The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo BEDMINSTER, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult pat
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA's strong prescription uptake continues: Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental NDA (sNDA) meeting with the U.S. Food and Drug Administration (FDA), the lumateperone sNDA submission for adjunctive treatment of major depressive disorder (MDD) is anticipated in the fourth quarter of 2024 Patient enrollment ongoing in ITI-1284 Phase 2 studies in generalized anxiety disorder
Piper Sandler upgraded Intra-Cellular Therapies from Neutral to Overweight and set a new price target of $92.00 from $68.00 previously
Robert W. Baird initiated coverage of Intra-Cellular Therapies with a rating of Outperform and set a new price target of $83.00
TD Cowen initiated coverage of Intra-Cellular Therapies with a rating of Outperform and set a new price target of $75.00
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA's strong prescription uptake continues: Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental NDA (sNDA) meeting with the U.S. Food and Drug Administration (FDA), the lumateperone sNDA submission for adjunctive treatment of major depressive disorder (MDD) is anticipated in the fourth quarter of 2024 Patient enrollment ongoing in ITI-1284 Phase 2 studies in generalized anxiety disorder
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024. To attend the live conference call by phone please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live and arc
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase CAPLYTA's strong prescription uptake continues: Q2 2024 CAPLYTA total prescriptions increased 36%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance raised to $650 to $680 million Announced positive Phase 3 results from Study 501 and Study 502 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disorder (MDD) Supplemental NDA (sNDA) submission for lumateperone as an adjunctive therapy to antidepressants in patients with MDD anticipated in the second half o
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
SC 13G - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for Lennar Corporation (NYSE:LEN) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. See how other analysts view this stock. Piper Sandler increased the price target for NVIDIA Corporation (NASDAQ:NVDA) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. See how other analyst
Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 4 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 0 2M Ago 3 2 0 0 0 3M Ago 2 1 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.18, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 1.96% from the previous
Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $94 to $100.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition. "I am excited to welcome Mr.
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors. Mr. Salas will serve as a member of the audit committee. "We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "Rene's extensive financial and life sciences advisory experience will be very valuable as we continue to grow our business and pursue our mission to develop innova
Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company. "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this manageme